Revolution Medicines, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RVMD Nasdaq 2836 www.revmed.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Revolution Medicines, Inc.

Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says - Sep 28th, 2026 9:58 am
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 - Sep 28th, 2026 6:00 am
Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold? - Sep 25th, 2026 3:42 am
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? - Sep 24th, 2026 8:35 pm
Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win? - Sep 23rd, 2026 12:13 am
Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing? - Sep 22nd, 2026 6:19 pm
Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE - Sep 22nd, 2026 4:11 pm
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib - Sep 22nd, 2026 6:55 am
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 - Sep 22nd, 2026 6:30 am
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - Sep 18th, 2026 7:00 am
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy? - Sep 17th, 2026 2:20 am
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift - Sep 16th, 2026 8:33 am
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. - Sep 16th, 2026 6:30 am
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer - Sep 14th, 2026 2:05 pm
MarketBeat Week in Review – 09/07 - 09/11 - Sep 12th, 2026 5:00 am
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs - Sep 11th, 2026 6:40 pm
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - Sep 11th, 2026 9:49 am
Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More. - Sep 10th, 2026 12:40 pm
Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says - Sep 10th, 2026 9:29 am